Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
License and other revenues
Expenses:
Research and development	7,207	8,041
General and administrative	7,123	3,997
Total expenses	14,330	12,038
Loss from operations	(14,330)	(12,038)
Interest income	843	364
Interest expense	(952)	(101)
Change in fair value of warrant and derivative liabilities	(17,301)	2,265
Other income	162	403
Net loss	$ (31,578)	$ (9,107)
Loss per common share - basic	$ (1.16)	$ (0.54)
Loss per common share - diluted	$ (1.16)	$ (0.54)
Weighted average number of common shares outstanding - basic	27,315,537	16,904,024
Weighted average number of common shares outstanding - diluted	27,315,537	16,904,024
Other comprehensive income (loss):
Change in unrealized (losses) gains related to available-for-sale debt securities	$ (118)	$ 64
Comprehensive loss	$ (31,696)	$ (9,043)